(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 March 2011 (10.03.2011)

PCT

(10) International Publication Number
WO 2011/028596 A1

(51) International Patent Classification:
A01N 57/00 (2006.01) *C07C 403/00* (2006.01)

(21) International Application Number:
PCT/US2010/046782

(22) International Filing Date:
26 August 2010 (26.08.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/239,855	4 September 2009 (04.09.2009)	US
61/297,324	22 January 2010 (22.01.2010)	US
61/348,767	27 May 2010 (27.05.2010)	US

(71) Applicant *(for all designated States except US)*: **GLAXOSMITHKLINE LLC** [US/US]; One Franklin Plaza, 200 North 16th Street, Philadelphia, PA 19102 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CHEN, Pingyun** [US/US]; c/o GaxoSmithKline, Global Patente, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **COUCH, Ricky** [US/US]; c/o GaxoSmithKline, Global Patente, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **DUAN, Maosheng** [CN/US]; c/o GaxoSmithKline, Global Patente, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **GRIMES, Richard, Martin** [GB/US]; c/o GaxoSmithKline, Global Patente, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **KAZMIERSKI, Wieslaw, Mieczyslaw** [US/US]; c/o GaxoSmithKline, Global Patente, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **NORTON, Beth, Adams** [US/US]; c/o GaxoSmithKline, Global Patente, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **TALLANT, Matthew** [US/US]; c/o GaxoSmithKline, Global Patente, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(74) Agent: **BRINK, Robert, H.**; GlaxoSmithKline, Global Patents, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: CHEMICAL COMPOUNDS



III

(57) **Abstract**: Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts.

WO 2011/028596 A1